Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

6.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.1K
Tumor Progression02:07

Tumor Progression

7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

16.6K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
16.6K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

15.1K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.1K
Cancer Survival Analysis01:21

Cancer Survival Analysis

797
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
797

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to: "On the Distinction Between Prognostic and Predictive Inference in Multicancer Early Detection" and "Interpretation of Survival Outcomes in Multicancer Early Detection Testing Requires Caution".

JCO precision oncology·2026
Same author

Assessment of human immunity to A/H3N2 influenza subclade K during 2025 emergence.

EBioMedicine·2026
Same author

Plasma signals of lung tumor promotion for molecular cancer prevention.

Cell·2026
Same author

Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation.

Nature machine intelligence·2026
Same author

Nociceptive innervation limits tertiary lymphoid structures to promote lung cancer.

Cell·2026
Same author

Subclonal immune evasion in non-small cell lung cancer.

Cancer cell·2026
Same journal

Itaconate in cancer immunity: Evidence, ambiguities, and translational barriers.

Trends in cancer·2026
Same journal

Patient-derived organoids in hematologic malignancies: Fidelity and translation beyond animals.

Trends in cancer·2026
Same journal

Precision neuro-oncology for children: Time to gear up!

Trends in cancer·2026
Same journal

Multi-omics analysis of extracellular vesicle cargo in cancer.

Trends in cancer·2026
Same journal

An immunological panacea for cancer-related cachexia.

Trends in cancer·2026
Same journal

Beyond one gene, one target: Next-generation precision oncology.

Trends in cancer·2026
See all related articles

Related Experiment Video

Updated: Feb 26, 2026

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K

Re-Evaluating Clonal Dominance in Cancer Evolution.

Rebecca A Burrell1, Charles Swanton2

  • 1Translational Cancer Therapeutics laboratory, Francis Crick Institute, 44 Lincoln's Inn Fields, London WC2A 3LY, UK.

Trends in Cancer
|July 26, 2017
PubMed
Summary
This summary is machine-generated.

Cancer tumours have diverse genetic subclones that influence disease progression. Understanding clonal heterogeneity and evolution is crucial for developing effective treatments for metastatic cancers.

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.6K
Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones
11:43

Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones

Published on: November 30, 2016

13.6K

Related Experiment Videos

Last Updated: Feb 26, 2026

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.6K
Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones
11:43

Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones

Published on: November 30, 2016

13.6K

Area of Science:

  • Oncology
  • Genetics
  • Evolutionary Biology

Background:

  • Tumours exhibit genetic heterogeneity with diverse subclones diverging early in growth.
  • Current cancer treatment strategies often rely on a simplified linear model of tumor evolution.
  • Emerging evidence highlights the significant impact of minor subclones on clinical outcomes.

Purpose of the Study:

  • To review the evidence for clonal heterogeneity in cancer.
  • To evaluate the importance of tumor subclones and their evolutionary dynamics (Darwinian and neutral).
  • To discuss the implications for clinical practice and trial design in managing heterogeneous metastatic disease.

Main Methods:

  • Literature review of studies on cancer clonal heterogeneity.
  • Analysis of evidence supporting Darwinian and neutral evolution in tumor subclones.
  • Evaluation of the impact of temporal and spatial heterogeneity on disease management.

Main Results:

  • Genetically heterogeneous subclones play a critical role in tumor progression and clinical outcomes.
  • Both Darwinian selection and neutral drift contribute to the evolution of tumor subclones.
  • Minor subclones can significantly influence disease course and treatment response.

Conclusions:

  • A paradigm shift towards understanding patient-specific cancer evolution is needed.
  • Clinical practice and trial designs must incorporate clonal heterogeneity for improved treatment efficacy.
  • Addressing tumor heterogeneity is essential for successful management of metastatic cancers.